Press release
Homozygous Familial Hypercholesterolemia Pipeline Drugs 2025 Report: Emerging Drugs, Innovative Therapies, Clinical Trial Updates, and Top Companies
Curious about the latest updates in the Homozygous Familial Hypercholesterolemia Pipeline? Click here to explore the therapies and trials making headlines @ Homozygous Familial Hypercholesterolemia Pipeline Outlook Report [https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Homozygous Familial Hypercholesterolemia Pipeline Report
On 10 October 2025, Arrowhead Pharmaceuticals conducted a study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE) period of the study. All placebo subjects who opt to continue will transition to active drug during the OLE Period.
* DelveInsight's Homozygous Familial Hypercholesterolemia Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Homozygous Familial Hypercholesterolemia treatment.
* The leading Homozygous Familial Hypercholesterolemia Companies such as Arrowhead Pharmaceuticals, Innovent Biologics, Akeso Biopharma, LIB Therapeutics LLC and others.
* Promising Homozygous Familial Hypercholesterolemia Therapies such as Lomitapide, Inclisiran, Zodasiran Injection, SHR-1918, Evinacumab, IBI306 , and others.
Want to know which companies are leading innovation in Homozygous Familial Hypercholesterolemia? Dive into the full pipeline insights @ Homozygous Familial Hypercholesterolemia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Homozygous Familial Hypercholesterolemia Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Homozygous Familial Hypercholesterolemia Pipeline Report also highlights the unmet needs with respect to the Homozygous Familial Hypercholesterolemia.
Homozygous Familial Hypercholesterolemia Overview
Homozygous familial hypercholesterolaemia (HoFH) is a rare and life-threatening disease originally characterized clinically by plasma cholesterol levels >13 mmol/L (>500 mg/dL), extensive xanthomas, and marked premature and progressive atherosclerotic cardiovascular disease (ACVD). Studies in cultured fibroblasts from these patients showed a severe defect in the ability to bind and internalize LDL particles, subsequently shown to be caused by mutations in both alleles of the gene encoding the LDL receptor (LDLR). Recent genetic insights, however, indicate that mutations in alleles of other genes, including APOB, PCSK9, and LDLRAP1, may be present in some individuals with HoFH.
Homozygous Familial Hypercholesterolemia Emerging Drugs Profile
* ARO-ANG 3: Arrowhead Pharmaceuticals
ARO-ANG3 is designed to reduce production of angiopoietin-like protein 3 (ANGPTL3), a liver synthesized inhibitor of lipoprotein lipase and endothelial lipase. ANGPTL3 inhibition has been shown to lower serum LDL, serum and liver triglyceride and has genetic validation as a novel target for cardiovascular disease. Currently, it is in Phase II stage of clinical trial evaluation to treat Homozygous Familial Hypercholesterolemia.
* Tafolecimab: Innovent Biologics
Tafolecimab injection, developed by Innovent, is an lgG2 fully human monoclonal antibody that can specifically bind to PCSK-9 and reduce LDL-C level by inhibiting PCSK-9-mediated low-density lipoprotein receptor (LDLR) endocytosis, subsequently enhancing the clearance of LDL-C, resulting in a reduction in LDL-C level.
If you're tracking ongoing Homozygous Familial Hypercholesterolemia Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Homozygous Familial Hypercholesterolemia Treatment Drugs [https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Homozygous Familial Hypercholesterolemia Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Homozygous Familial Hypercholesterolemia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Homozygous Familial Hypercholesterolemia Treatment.
* Homozygous Familial Hypercholesterolemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Homozygous Familial Hypercholesterolemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Homozygous Familial Hypercholesterolemia market.
Homozygous Familial Hypercholesterolemia Companies
Arrowhead Pharmaceuticals, Innovent Biologics, Akeso Biopharma, LIB Therapeutics LLC and others.
Homozygous Familial Hypercholesterolemia Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Inhalation
* Inhalation/Intravenous/Oral
* Intranasal
* Intravenous
* Intravenous/ Subcutaneous
* NA
* Oral
* Oral/intranasal/subcutaneous
* Parenteral
* Subcutaneous
Homozygous Familial Hypercholesterolemia Products have been categorized under various Molecule types such as,
* Antibody
* Antisense oligonucleotides
* Immunotherapy
* Monoclonal antibody
* Peptides
* Protein
* Recombinant protein
* Small molecule
* Stem Cell
* Vaccine
From emerging drug candidates to competitive intelligence, the Homozygous Familial Hypercholesterolemia Pipeline Report covers it all - check it out now @ Homozygous Familial Hypercholesterolemia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Homozygous Familial Hypercholesterolemia Pipeline Report
* Coverage- Global
* Homozygous Familial Hypercholesterolemia Companies- Arrowhead Pharmaceuticals, Innovent Biologics, Akeso Biopharma, LIB Therapeutics LLC and others.
* Homozygous Familial Hypercholesterolemia Therapies- Lomitapide, Inclisiran, Zodasiran Injection, SHR-1918, Evinacumab, IBI306 , and others.
* Homozygous Familial Hypercholesterolemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Homozygous Familial Hypercholesterolemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Homozygous Familial Hypercholesterolemia Treatment landscape in this detailed analysis @ Homozygous Familial Hypercholesterolemia Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Homozygous Familial Hypercholesterolemia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Homozygous Familial Hypercholesterolemia - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ARO-ANG 3: Arrowhead Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Homozygous Familial Hypercholesterolemia Key Companies
* Homozygous Familial Hypercholesterolemia Key Products
* Homozygous Familial Hypercholesterolemia- Unmet Needs
* Homozygous Familial Hypercholesterolemia- Market Drivers and Barriers
* Homozygous Familial Hypercholesterolemia- Future Perspectives and Conclusion
* Homozygous Familial Hypercholesterolemia Analyst Views
* Homozygous Familial Hypercholesterolemia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=homozygous-familial-hypercholesterolemia-pipeline-drugs-2025-report-emerging-drugs-innovative-therapies-clinical-trial-updates-and-top-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Homozygous Familial Hypercholesterolemia Pipeline Drugs 2025 Report: Emerging Drugs, Innovative Therapies, Clinical Trial Updates, and Top Companies here
News-ID: 4226088 • Views: …
More Releases from ABNewswire
Oral Surgeon Huntington Beach Practice Elevates Standards for Patient Comfort an …
Huntington Beach oral surgery practice, The Wisdom Teeth Guru sets new patient care standards through specialized training, advanced sedation options, and efficient same-day treatment capabilities under Dr. Kiet Tran's leadership.
A Huntington Beach dental practice has gained recognition for transforming how patients experience oral surgery procedures. The Wisdom Teeth Guru [https://www.google.com/maps/place/The+Wisdom+Teeth+Guru/data=!4m2!3m1!1s0x0:0x98592ab69d239d3a?sa=X&ved=1t:2428&hl=en&ictx=111], led by Dr. Kiet Tran, has established new benchmarks in patient care through advanced techniques and a commitment to making…
Columbus Moving Services Expands as Moving Ahead Services Responds to Central Oh …
Moving Ahead Services expands coverage across 23 Central Ohio communities, offering flexible moving solutions with regulatory compliance and community partnerships that support both residential and commercial relocations.
The Central Ohio region continues to experience steady population growth, and Moving Ahead Services has positioned itself to address the increasing demand for professional relocation assistance. The expansion of Columbus moving services reflects the company's two decades of experience serving the area, with operations…
What Does a Full-Service Move Include? Moving Companies Report Surge in Demand f …
Greenville homeowners increasingly prefer comprehensive relocation packages that handle packing, furniture assembly, transportation, and setup. Professional services reduce stress and damage while streamlining transitions.
Homeowners and renters across Greenville are opting for comprehensive relocation packages as the complexity of modern moves continues to grow. Recent trends show that families and businesses alike are seeking moving companies for an end-to-end solution that eliminates the stress traditionally associated with changing addresses. This shift…
Local Garage Door Company Sees Surge in Emergency Repairs Following Extreme Temp …
AA Garage Door LLC reports increased emergency repairs across St. Paul as extreme cold causes cable failures and spring breaks. Technicians respond to urgent service needs throughout Twin Cities neighborhoods affected by harsh winter conditions.
Recent weather patterns across the St. Paul region have created unprecedented challenges for homeowners, with plummeting temperatures causing significant strain on residential overhead door systems. AA Garage Door LLC, a trusted garage door company [https://maps.google.com/maps?ll=44.91738,-93.190993&z=16&t=h&hl=en&gl=PH&mapclient=embed&cid=15111651982362415047&q=garage+door+company&oq=garage+door+company+near+me] serving…
More Releases for Homozygous
Homozygous Familial Hypercholesterolemia Market Outlook 2024-2034
Introduction
Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening genetic disorder characterized by extremely high cholesterol levels from birth. Patients with HoFH are at a very high risk of premature atherosclerotic cardiovascular disease (ASCVD), often developing complications as early as childhood. While the condition is rare-affecting approximately 1 in 160,000 to 300,000 individuals globally-it has become a major focus for pharmaceutical innovation due to the severity of the disease and the…
Homozygous Familial Hypercholesterolemia (HoFH) Market Massive Growth opportunit …
Introduction
Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic lipid disorder characterized by extremely high low-density lipoprotein cholesterol (LDL-C) levels from birth, often exceeding 500 mg/dL. Caused by mutations in both alleles of the LDLR, APOB, or PCSK9 genes, HoFH leads to early-onset atherosclerosis, cardiovascular disease, and premature mortality if untreated.
Historically, management relied on lipid-lowering agents, LDL apheresis, and lifestyle modifications. However, the last decade has witnessed a paradigm shift with…
Homozygous Familial Hypercholesterolemia Market 2025 | Market Growth, Genetic Sc …
Homozygous Familial Hypercholesterolemia Market reached US$ 83.7 million in 2022 and is expected to reach US$ 101.8 million by 2030 growing with a CAGR of 2.5% during the forecast period 2023-2030, according to DataM Intelligence research report, as per DataM intelligence research report.
Homozygous Familial Hypercholesterolemia Market: Recent Industry Developments
United States
✅ Regeneron announced the FDA extension of Evkeeza use to children aged 5-11 with HoFH, making it the first ANGPTL3 inhibitor…
New Syndrome: seemingly unrelated symptoms have a common cause in patients with …
The International H63D Mutation Research Consortium www.h63d-syndrome.org has announced the discovery of "Typ-2 H63D Syndrome", a genetic disease caused by a homozygous mutation of the HFE gene H63D. The research work, which spanned 12 years, uncovered that the mutation is responsible for a wide range of symptoms due to micro-inflammations, which can be challenging to diagnose without the proper knowledge and testing.
While classic Typ-1 H63D Syndrome is a rare disorder…
Latest Homozygous Familial Hypercholesterolemia Treatment Market Research | Comp …
Homozygous Familial Hypercholesterolemia Treatment Market
Market Strides has added a new report titled, “Global Homozygous Familial Hypercholesterolemia Treatment Market Professional Report 2027” to its vast repository of research reports. This is a comprehensive report focused on the current and future prospects of the Global Homozygous Familial Hypercholesterolemia Treatment Market. The report also mentions the impact of the coronavirus pandemic on the market. Furthermore, the study includes the steps the leading industry…
Homozygous Familial Hypercholesterolemia Treatment Market Size - Technological A …
Up Market Research (UMR) has published a latest market research report on Global Homozygous Familial Hypercholesterolemia Treatment Market. The global report is prepared in collaboration with the leading industry experts and dedicated research analyst team to provide an enterprise with in-depth market insights and help them to take crucial business decisions. This report covers current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.
The…
